Can I read Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial on EtoBox?

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial by Caicun Zhou; Minu K Srivastava; Hao Xu; Enriqueta Felip; Heather Wakelee; Nasser Altorki; Martin Reck; Rüdiger Liersch; Anna Kryzhanivska; Satoshi Oizumi; Hiroshi Tanaka; John Hamm; Steven L McCune; Elizabeth Bennett; Barbara Gitlitz; Virginia McNally; Marcus Ballinger; Mark McCleland; Wei Zou; Meghna Das Thakur; Silvia Novello is a Medicine article available to read on EtoBox.

What is Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial about?

## Background Tumor samples from the phase III IMpower010 study were used to compare two programmed death-ligand 1 (PD-L1) immunohistochemistry assays (VENTANA SP263 and Dako 22C3) for identification of PD-L1 patient subgroups (negative, positive, low, and high expression) and their predictive value for adjuvant atezolizumab compared with best supportive care (BSC) in resectable early-stage non-small cell lung cancer (NSCLC). ## Methods PD-L1 expression was assessed by the SP263 assay, which measured the percentage of tumor cells with any membranous PD-L1 staining, and the 22C3 assay, which scored the percentage of viable tumor cells showing partial or complete membranous PD-L1 staining. ## Results When examining the concordance at the PD-L1-positive threshold (SP263: tumor cell (TC)≥1%; 22C3: tumor proportion score (TPS)≥1%), the results were concordant between assays for 83% of the samples. Similarly, at the PD-L1–high cut-off (SP263: TC≥50%; 22C3: TPS≥50%), the results were concordant between assays for 92% of samples. The disease-free survival benefit of atezolizumab over BSC was comparable between assays for PD-L1-positive (TC≥1% by SP263: HR, 0.58 (95% CI: 0.40 to 0.85) vs TP

Who reads Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial?

Author

Caicun Zhou; Minu K Srivastava; Hao Xu; Enriqueta Felip; Heather Wakelee; Nasser Altorki; Martin Reck; Rüdiger Liersch; Anna Kryzhanivska; Satoshi Oizumi; Hiroshi Tanaka; John Hamm; Steven L McCune; Elizabeth Bennett; Barbara Gitlitz; Virginia McNally; Marcus Ballinger; Mark McCleland; Wei Zou; Meghna Das Thakur; Silvia Novello

Publisher

BMJ

Published

2023

Field

Medicine (Health Sciences)